Verve Therapeutics Inc (VERV) Stock Price, Quote & News

Company Profile

Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 603 0070

Website: www.vervetx.com

Address:

201 Brookline Avenue, Suite 601, Boston, United States

RocroBio Oct. 4 at 10:12 PM

$EDIT $NTLA $PRME $VERV

0 · Reply

BIOTECH_GURU Sep. 24 at 1:13 PM

$VERV $NTLA $QURE $ILMN How am doing?

1 · Reply

BIOTECH_GURU Sep. 22 at 5:15 AM

$XBI $VERV $MTSR rumors floating. $VKTX $ALT next. Billions to be made, you betya they will get a better offer than $7.3B.

1 · Reply

lecorb Aug. 27 at 7:14 PM

$NXTT $SUPX $VERV $NUKK

0 · Reply

Gladiator007 Aug. 24 at 3:12 PM

$CAPR $SRPT $VERV was sold for 1 3 Billion with zero drugs on phase III, zero approved drugs, and zero revenue. Clueless jkr

0 · Reply

RocroBio Aug. 15 at 3:01 PM

$CRSP $EDIT $NTLA $PRME $VERV

0 · Reply

NwordFslur Aug. 8 at 11:49 PM

$VKTX movement reminds me of $VERV before it got bought out

0 · Reply

NVDAMillionaire Jul. 28 at 8:19 PM

$VERV Outstanding article that hits the mark on VERV's current state. So if you want to refresh your VERV insights or learn about VERV from scratch, this is a must read. https://beyondspx.com/article/verve-therapeutics-a-single-course-vision-for-cardiovascular-disease-backed-by-lilly-s-bet-verv

0 · Reply

biotech Jul. 28 at 6:03 PM

$SGMO ASGCT Nov. 20-21, 2025 delve into the latest advancements in targeted gene editing delivery strategies in vivo Invited Speaker: $SGMO Sonia Vallabh, PhD (Broad Institute) Talk Topic: AAV-mediated #epigenetic #editing for #prion disease also $VERV and $BEAM attending https://www.asgct.org/events/breakthroughs/program

1 · Reply

NwordFslur Jul. 28 at 2:09 PM

$VERV what can I do with my options? Robinhood doesn't let me trade them. $5 strike

0 · Reply

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

LLY

Jul 24, 2025, 8:00 AM EDT - 2 months ago

Lilly and Verve announce expiration of Verve tender offer

LLY

Jun 18, 2025, 11:28 PM EDT - 3 months ago

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

LLY

Jun 17, 2025, 12:57 PM EDT - 3 months ago

Lilly to buy gene-editing partner Verve for $1.3 billion

LLY

Jun 17, 2025, 10:30 AM EDT - 3 months ago

JBLU Cutting Back Flights, Solar Stocks Sell, LLY Bid for VERV

LLY FSLR JBLU RUN ENPH JETS SEDG

Jun 17, 2025, 8:31 AM EDT - 3 months ago

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

RGC SAGE

Jun 17, 2025, 7:55 AM EDT - 3 months ago

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

LLY

Jun 17, 2025, 6:54 AM EDT - 3 months ago

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say

LLY

Jun 17, 2025, 6:45 AM EDT - 3 months ago

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

LLY

Jun 17, 2025, 5:33 AM EDT - 3 months ago

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%.

LLY

Jun 16, 2025, 7:49 PM EDT - 4 months ago

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports

LLY

Jun 2, 2025, 4:05 PM EDT - 4 months ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 28, 2025, 7:00 AM EDT - 4 months ago

Verve Therapeutics to Participate in Upcoming Investor Conferences

May 20, 2025, 5:47 AM EDT - 4 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT NTLA VANI

May 14, 2025, 7:00 AM EDT - 5 months ago

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

Apr 16, 2025, 10:56 AM EDT - 6 months ago

Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'

LLY

Apr 14, 2025, 11:34 AM EDT - 6 months ago

Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose

Apr 14, 2025, 7:00 AM EDT - 6 months ago

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Apr 11, 2025, 7:00 AM EDT - 6 months ago

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Mar 24, 2025, 7:00 AM EDT - 7 months ago

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

Feb 27, 2025, 7:00 AM EST - 7 months ago

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 31, 2025, 11:11 AM EST - 8 months ago

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm

Jan 29, 2025, 7:00 AM EST - 8 months ago

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Jan 26, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation

Jan 22, 2025, 10:00 AM EST - 9 months ago

Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 19, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation

Jan 15, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Shareholders to Connect

Jan 12, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation

Jan 8, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation

Jan 5, 2025, 10:00 AM EST - 9 months ago

Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 2, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect

Dec 29, 2024, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Stockholders to Connect

Dec 26, 2024, 10:00 AM EST - 10 months ago

Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Dec 22, 2024, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Stockholders to Learn More About the Investigation

Dec 18, 2024, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation

Dec 15, 2024, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out

Oct 27, 2024, 11:00 AM EDT - 1 year ago

DEADLINE APPROACHING: Verve Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm

Oct 25, 2024, 11:00 AM EDT - 1 year ago

Verve Therapeutics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Oct 22, 2024, 6:05 PM EDT - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics

RocroBio Oct. 4 at 10:12 PM

$EDIT $NTLA $PRME $VERV

0 · Reply

BIOTECH_GURU Sep. 24 at 1:13 PM

$VERV $NTLA $QURE $ILMN How am doing?

1 · Reply

BIOTECH_GURU Sep. 22 at 5:15 AM

$XBI $VERV $MTSR rumors floating. $VKTX $ALT next. Billions to be made, you betya they will get a better offer than $7.3B.

1 · Reply

lecorb Aug. 27 at 7:14 PM

$NXTT $SUPX $VERV $NUKK

0 · Reply

Gladiator007 Aug. 24 at 3:12 PM

$CAPR $SRPT $VERV was sold for 1 3 Billion with zero drugs on phase III, zero approved drugs, and zero revenue. Clueless jkr

0 · Reply

RocroBio Aug. 15 at 3:01 PM

$CRSP $EDIT $NTLA $PRME $VERV

0 · Reply

NwordFslur Aug. 8 at 11:49 PM

$VKTX movement reminds me of $VERV before it got bought out

0 · Reply

NVDAMillionaire Jul. 28 at 8:19 PM

0 · Reply

biotech Jul. 28 at 6:03 PM

1 · Reply

NwordFslur Jul. 28 at 2:09 PM

$VERV what can I do with my options? Robinhood doesn't let me trade them. $5 strike

0 · Reply

BIOTECH_GURU Jul. 26 at 7:41 AM

$VERV this was fun. I expected the management to wait for the data then we would make much more than the 90% permium. But I will take the W and watch Lilly reap the spoils. For the record, ai think this drug will be worth 10b annual sales.

0 · Reply

WM_trader Jul. 25 at 3:59 PM

$VERV What are the expectations here with the news?

0 · Reply

Okadarlan Jul. 25 at 3:49 PM

$VERV big crash immenent.

1 · Reply

masonat Jul. 25 at 1:34 PM

$VERV have been keeping up with the company and posting my thoughts here for a few years now. Was fun while it lasted! ✌🏼

0 · Reply

I_killed_the_kraken Jul. 25 at 1:01 PM

$VERV watching today, huge news, currently halted

0 · Reply

AlertsAndNews Jul. 25 at 12:55 PM

$VERV $LLY Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk VERV is t-12 halted still.

0 · Reply

MKRReformed Jul. 25 at 12:50 PM

$VERV officially completed via $LLY Grats to all bulls

0 · Reply

michipetruzale Jul. 25 at 8:03 AM

$VERV whats happening with my shares?

1 · Reply

TwongStocks Jul. 24 at 7:10 PM

$VERV NASDAQ Equity Corporate Actions Alert #2025 - 391 (UPDATED) Information Regarding the Tender Offer of Verve Therapeutics, Inc. (VERV) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-391 The tender offer by Eli Lilly & Co $LLY to acquire all of the outstanding common stock of Verve Therapeutics, Inc. $VERV expired one minute after 11:59 p.m. ET, on July 23, 2025. The subsequent merger is tentatively scheduled to close prior to the market open on July 25, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on July 24, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (July 25th) and will be suspended July 28, 2025. Tender offer is $10.50 & 1 Contingent Value Right (CVR) for each share of VERV held

0 · Reply

Mergerbrief Jul. 23 at 12:10 PM

$VERV / $LLY - Tender Offer Expires MergerBrief.com

0 · Reply

OMillionaires Jul. 21 at 2:39 PM

$EDIT $260 mil market cap with $221 mil cash 10.5% short interest $LLY 's $VERV buyout seems to have been a floor and spark in the gene editing space... Blue skies over that $3.30 handle from Feb

1 · Reply

GeneInvestingTwitter Jul. 21 at 2:30 PM

$NTLA yes tons! $VERV buyout by Lily. Liu buying many times $PRME 51 million insider $CRSP buy last week

2 · Reply

Market Cap	992.16M
Revenue (ttm)	32.33M
Net Income (ttm)	-198.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-614.63%
Debt to Equity Ratio	0.00

Volume	10,306,600
Avg Vol	5,522,362
Day's Range	N/A - N/A
Shares Out	89.14M
Stochastic %K	66%
Beta	2.23
Analysts	Sell
Price Target	$14.25